Moss, 30 September 2024
 
Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic
tests, is pleased to announce that it has been granted a European patent for its
novel reference method which can be used to accurately assign values to
calibrators used in diagnostic assays for the determination of the concentration
of NT-proBNP in blood samples.

Gentian has been informed that our international patent application
PCT/EP2022/077433 entitled "Novel method for determining a concentration of
N-terminal pro-hormone BNP (NT-proBNP) in a sample" is patentable in its entire
set of claims. The patent application will now enter the national and regional
phases, where validated patents will be issued in the designated nations and
regions. The patented method utilizes a robust mass spectrometry-based approach,
specifically LC-MS/MS, to quantify the total amount of NT-proBNP in a sample,
regardless of its glycosylation status. This advanced technique provides a
reliable reference method, which can be used to calibrate NT-proBNP immunoassays
and harmonize existing NT-proBNP diagnostic methods, ensuring higher accuracy
and reliability.

"Our new method can support more reliable clinical measurements of NT-proBNP",
says Njaal Kind, acting CEO of Gentian Diagnostics ASA. "With this patented
reference method, Gentian demonstrates its commitment to the development of
harmonized NT-proBNP measurements which may be of significant benefit to
healthcare providers and patients". 

About Gentian Diagnostics 
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in
vitro diagnostic reagents. Gentian's expertise and focus lies within homogenous
immunoassays, specifically infections, inflammations, kidney failures and
congestive heart failures. By converting existing and clinically relevant
biomarkers to the most efficient automated, high-throughput analysers, the
company contributes to saving costs and protecting life. Gentian is
headquartered in Moss, Norway, serving the global human and veterinary
diagnostics markets through sales and representative offices in Sweden, USA, and
China. For more information, please visit www.gentian.com. 

IR contact: 
Njaal Kind, CEO 
njaal.kind@gentian.no 
+47 919 06 525 (mobile)